QT Variability Pre and Post Cardioversion (DCCV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00885391
Recruitment Status : Completed
First Posted : April 22, 2009
Last Update Posted : December 11, 2014
National Institutes of Health (NIH)
Wake Forest University Health Sciences
Information provided by (Responsible Party):
Dawood Darbar, Vanderbilt University

Brief Summary:
The purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.

Condition or disease
Atrial Fibrillation

Detailed Description:
Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.

Study Type : Observational
Actual Enrollment : 219 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: QT Variability Pre & Post Cardioversion in Patient's With Atrial Fibrillation
Study Start Date : January 2007
Actual Primary Completion Date : March 2012
Actual Study Completion Date : March 2012

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. QT variability before and after direct current cardioversion [ Time Frame: 1.5 ]

Biospecimen Retention:   Samples With DNA
Blood sample

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Cardiology Clinic Hospital inpatient

Inclusion Criteria:

  • At least 21 years of age
  • Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center

Exclusion Criteria:

  • Undergoing emergent DC-Cardioversion of atrial fibrillation for hemodynamic instability
  • Undergoing DC-Cardioversion for post-cardiac surgery
  • Dual chamber pacemakers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00885391

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-0575
Sponsors and Collaborators
Vanderbilt University
National Institutes of Health (NIH)
Wake Forest University Health Sciences
Principal Investigator: Dawood Darbar, M.D., Ph.D., F.A.C.C. Vanderbilt University Medical Center

Responsible Party: Dawood Darbar, Associate Professor of Medicine and Pharmacology, Vanderbilt University Identifier: NCT00885391     History of Changes
Other Study ID Numbers: 060908
R01HL085690-01A2 ( U.S. NIH Grant/Contract )
First Posted: April 22, 2009    Key Record Dates
Last Update Posted: December 11, 2014
Last Verified: December 2014

Keywords provided by Dawood Darbar, Vanderbilt University:
Atrial Fibrillation
Direct Current Cardioversion
QT Interval

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes